What is Jade Biosciences, Inc. (JBIO) stock price today?

Jade Biosciences, Inc. (JBIO) currently trades at $24.40 per share. The stock has a market capitalization of $1.32B and a P/E ratio of —x.

Is JBIO stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Jade Biosciences, Inc. has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is 4.18.

Is Jade Biosciences, Inc. financially healthy?

Jade Biosciences, Inc.'s Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of 4.18 places it in the safe zone.

JBIO

Jade Biosciences, Inc.

NASDAQ: JBIO · HEALTHCARE · BIOTECHNOLOGY

$24.40

+9.32% today

Updated 2026-04-30

Market cap

$1.32B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.19

Dividend yield

—

52W range

$7 – $28

Volume

0.6M

Market cap

$1.32B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-3.19

Dividend yield

—

52W range

$7 – $28

Volume

0.6M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

4.2

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$30.14

+23.52%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Altman Z 4.18 — safe zone

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-33.65M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	—	—	—	$0.00	$0.00
Net income	$-51.51M	$-75.52M	$-69.63M	$-127.41M	$-67.58M
EPS	—	—	—	—	$-3.19
Free cash flow	$-39.32M	$-56.92M	$-71.20M	$-94.89M	$-33.65M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
JBIO	$1.32B	26	4.3	3.0	5.0	8.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Jade Biosciences, Inc. trades at $24.40. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 4.18, it sits in the safe zone.

Frequently asked questions

What is Jade Biosciences, Inc.'s stock price?

Jade Biosciences, Inc. (JBIO) trades at $24.40.

Is Jade Biosciences, Inc. overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of Jade Biosciences, Inc. (JBIO)?

The analyst target price is $30.14, representing +23.5% upside from the current price of $24.40.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

4.18 — safe zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-89.20%

Beta—

50D MA$16.37

200D MA$12.25

Shares out0.05B

Float0.03B

Short ratio—

Avg volume0.6M

Performance

1 week+27.72%

1 month+62.29%

3 months+55.44%

YTD+48.09%

1 year—

3 years—

5 years—

Compare

JBIO vs LLY →JBIO vs JNJ →JBIO vs ABBV →Stock screener →